Related Experiment Videos
A1 adenosine receptors and their ligands: overview and recent developments
1University of Bonn, Pharmaceutical Institute, Department of Pharmaceutical Chemistry, Germany. christa.mueller@uni-bonn.de
Farmaco (Societa Chimica Italiana : 1989)
|May 12, 2001
Summary
Selective adenosine receptor (AR) modulators, particularly for A1AR, face challenges in human selectivity and solubility. Research is exploring partial agonists and plant-derived compounds for improved therapeutic potential.
Area of Science:
- Pharmacology
- Medicinal Chemistry
Background:
- Decades of research have yielded potent adenosine receptor (AR) agonists and antagonists selective for the A1AR subtype.
- Challenges remain regarding selectivity in humans versus rats and against newer AR subtypes (A3, A2B).
Purpose of the Study:
- To review the development of A1AR modulators.
- To highlight challenges and future directions in A1AR antagonist and agonist research.
Main Methods:
- Review of existing literature on A1AR agonists and antagonists.
- Discussion of compound selectivity, partial agonism, and solubility issues.
- Exploration of natural product contributions and PET imaging agents.
Main Results:
- Development of selective A1AR modulators is ongoing, but human selectivity and solubility are key concerns.
- Partial agonists offer a potential route to reduced side effects.
- Medicinal plants contain A1AR active compounds, and radiolabeled antagonists are available for PET studies.
Conclusions:
- Further investigation is needed to clarify the pharmacological differences between neutral antagonism and inverse agonism at A1 ARs.
- Addressing selectivity, solubility, and understanding diverse mechanisms are crucial for advancing A1AR-targeted therapeutics.